Regeneron Axokine (correction)
Executive Summary
Regeneron is developing the Phase III obesity agent Axokine without a partner; "The Pink Sheet" (Sept. 15, p. 25) incorrectly stated that Aventis was co-developing the ciliary neurotrophic factor...
You may also be interested in...
Bayer Confident CureVac COVID Pact Will Be A Success
CEO Werner Baumann admits he was skeptical at first as to whether the German group had the necessary know-how to manufacture vaccines but the firm's expertise in the development of biotech products has strengthened his belief Bayer can deliver.
EMA Works On Defining Metadata From RWD Sources
As part of its big data initiative, the European Medicines Agency is supporting projects that will help identify appropriate real-world data sources for regulatory decision making.
UCB And Microsoft Expand AI Tie-Up Beyond COVID-19
Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: